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ABSTRACT
Proliferating cell nuclear antigen (PCNA) is a multi-
functional protein present in the nuclei of eukaryotic
cells that plays an important role as a component of
the DNA replication machinery, as well as DNA repair
systems. PCNA was recently proposed as a potential
non-oncogenic target for anti-cancer therapy. In this
study, using the Systematic Evolution of Ligands by
EXponential enrichment (SELEX) method, we devel-
oped a short DNA aptamer that binds human PCNA.
In the presence of PCNA, the anti-PCNA aptamer in-
hibited the activity of human DNA polymerase  and
 at nM concentrations. Moreover, PCNA protected
the anti-PCNA aptamer against the exonucleolytic
activity of these DNA polymerases. Investigation of
the mechanism of anti-PCNA aptamer-dependent in-
hibition of DNA replication revealed that the ap-
tamer did not block formation, but was a component
of PCNA/DNA polymerase  or  complexes. Addi-
tionally, the anti-PCNA aptamer competed with the
primer-template DNA for binding to the PCNA/DNA
polymerase  or  complex. Based on the observa-
tions, a model of anti-PCNA aptamer/PCNA complex-
dependent inhibition of DNA replication was pro-
posed.
INTRODUCTION
Proliferating cell nuclear antigen (PCNA) is a key compo-
nent of the DNA replication and DNA repair machiner-
ies in eukaryotes (1). Although PCNA was long consid-
ered a nuclear protein, recent studies indicate that it may
also function in the cytoplasm, where it has been proposed
to regulate neutrophil lifespan (2), and on the cell surface,
where it acts as a ligand for the natural cytotoxicity re-
ceptor NKp44 to regulate the activation of natural killer
cells (3). The PCNA monomer is composed of N- and C-
terminal domains connected by an inter-domain connect-
ing loop (IDCL). PCNA monomers spontaneously form
a trimeric ring-like structure (4,5). During DNA replica-
tion, the PCNA trimer is loaded onto theDNAdouble helix
by the Replication Factor C (RFC) complex, and slides bi-
directionally along the DNA duplex (6). In recent decades,
a large number of proteins involved in DNA replication, re-
pair, cell cycle control, epigenetic regulation, cell survival
and metabolism have been shown to interact with PCNA
(7,8). PCNA not only functions as a docking platform for
proteins involved inDNAmetabolism, but it also stimulates
the activity of some enzymes such asDNApolymerase (pol)
, Fen1 andDNA ligase I (9,10). Analysis of the amino acid
sequences of PCNA-interacting proteins led to the identi-
fication of the PCNA-Interacting Protein (PIP)-box motif,
characterized by the consensus sequence Q-xx-(h)-x-x-(a)-
(a), where h and a represent residues with moderately hy-
drophobic and aromatic side chains, respectively, while x is
any residue (8,11). Other motifs have since been reported,
including theKA-box (12) and theAlkB homolog 2 PCNA-
interacting motif (APIM) identified in the sequence of hu-
man AlkB2 homolog 2, an oxidative demethylase involved
in DNA damage repair (13). The affinity between PCNA
and PCNA-interacting proteins can be controlled by post-
translational modifiers (14).
The documented functions of PCNA in DNA replication
and repair led to the proposal that PCNA may be a non-
oncogenic target for anti-cancer therapy (15–17). It is antic-
ipated that the application of molecules inhibiting binding
between PCNA and PCNA-interacting proteins, in combi-
nation with other compounds directed at oncogenic targets,
could increase the effectiveness of anti-cancer therapies.
Previous attempts to block interactions between PCNA
and PCNA-interacting proteins have focused on peptides
and small molecules (18,19). However, the toxicity and im-
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munogenicity of these molecules for human was not tested.
Therefore, identifying alternative drug candidates targeting
PCNA remains a priority. Among the molecules that could
potentially fulfil such criteria are DNA aptamers, single-
stranded deoxyoligonucleotides with the ability to adopt
different secondary and tertiary structures. Aptamers can
recognize a broad range of targets including low molecu-
lar weight molecules such as ions, vitamins and antibiotics,
as well as high molecular weight molecules including en-
zymes and antibodies. DNAaptamers have been extensively
studied as potential drug candidates and diagnostic tools.
This is mainly due to their relatively inexpensive synthe-
sis, low immunogenicity, high specificity and strong affin-
ity for specific targets. Moreover, simple chemical modifi-
cation of DNA aptamers can increase their specificity and
stability (20,21). For example, the DNA aptamer AS1411
was shown in vitro to effectively eliminate cancer cells over-
expressing nucleolin on their surface (22). Systematic Evo-
lution of Ligands by EXponential enrichment (SELEX) is
the classical DNA aptamer selection method first described
in the early 1990s (23,24). In SELEX, a target molecule is
exposed to a synthetic ssDNA aptamer library composed
of 1014−1015 different oligonucleotides. The ssDNA frag-
ments bound to the target are amplified using polymerase
chain reaction (PCR), and the new pool of ssDNA for the
next round of selection is prepared. After several rounds of
selection, aptamers specific to target molecules are usually
obtained. In the present study, we identified and character-
ized a PCNA-binding DNA aptamer capable of blocking
DNA replication. The possible mechanism of anti-PCNA
aptamer/PCNA complex-dependentDNA replication inhi-
bition is discussed.
MATERIALS AND METHODS
Chemicals, plasmids and antibodies
All chemicals used for buffers and solutions were obtained
from Sigma-Aldrich and Merck unless mentioned other-
wise. Oligonucleotides were obtained from IBA GmbH
(Germany). The template plasmid pDNR-LIB harbor-
ing human PCNA cDNA was purchased from ImaGenes
GmbH (Germany). Primary anti-DNA pol  p125 sub-
unit goat polyclonal antibody (sc-8796), anti-DNA pol ε
p261 subunit monoclonal antibody (CRL-2284) and anti-
human PCNA monoclonal antibody (PC10) were pur-
chased from Santa Cruz (USA), ATCC (UK) and Sigma-
Aldrich (USA), respectively. Anti-human PCNA rabbit
polyclonal antiserum was produced at Kyushu University.
Goat anti-mouse IgG conjugated with HRP and goat anti-
rabbit IgG conjugatedwithHRP secondary antibodies were
purchased from Bio-Rad (USA), while rabbit anti-goat IgG
conjugated with HRP was from Zymed Laboratories.
Cloning, protein production and purification
The open reading frame (ORF) encoding human PCNA
was amplified using Phusion High-Fidelity DNA poly-
merase (Thermo Fisher Scientific, Lithuania). The
PCR product amplified using primers HisPCNAF
(5′-CAGGATCCGATGTTCGAGGCGCGCCTGGT
CCAGGGCTC-3′) and HisPCNAR (5′-CCCAAGCTT
CTAAGATCCTTCTTCATCCTCG-3′) was cloned into
the pETDuet-1 vector (Novagen, Germany) using BamHI
andHindIII restriction enzymes to create a vector encoding
HisTag-PCNA. The PCR product amplified using primers
StrepPCNAF (5′-CATATGGCTAGCTGGAGCCAC
CCGCAGTTCGAAAAAGGCGCCATGTTCGAGGC
GCGCCTGGTCCAGGGCTC-3′) and StrepPCNAR
(5′-GCGGATCCCTAAGATCCTTCTTCATCCTCGA
TCTTG-3′) was cloned into the pJET1.2 vector (Thermo
Fisher Scientific), digested with NdeI and BamHI re-
striction enzymes and subcloned into the pET29a vector
(Novagen) to create a plasmid encoding StrepTag-PCNA.
TheEscherichia coliBL21 (DE3) CodonPlus-pRIL strain
was used for protein production. Cells carrying plasmids
harboring human PCNA were grown at 37◦C using LB
medium supplemented with 25 mg/l chloramphenicol and
50 mg/l kanamycin (pET29a) or 100 mg/l ampicillin
(pETDuet-1). When the absorbance at 600 nm (OD600) of
the culture reached ∼0.6, protein overexpression was in-
duced using 1 mM isopropyl -D-1-thiogalactopyranoside
(IPTG). Culturing was continued with vigorous shaking
at 37◦C for 4 h. Cells were harvested by centrifugation
(5 min, 8000 × g, 4◦C). HisTag-PCNA and StrepTag-
PCNA bacteria were resuspended in binding buffer A (50
mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH
8.0) and buffer B (100 mM TRIS–HCl pH 8.0, 150 mM
NaCl, 1 mM ethylenediaminetetraacetic acid (EDTA)), re-
spectively. Sonication was then performed for 8 min (5 s
pulses and 10 s pauses) using an Omni-Ruptor 4000 sonica-
tor (OMNI International Inc., USA). HisTag-PCNA and
StrepTag-PCNA lysates were centrifuged (30 min, 30 000
× g, 4◦C) and supernatants were loaded onto HisTrap FF
Ni Sepharose (GE Healthcare, Sweden) and Strep-Tacin
columns (IBA GmbH), respectively. Protein purification
was performed according to the protocols supplied by the
manufacturers. After elution from the nickel resin, HisTag-
PCNA was dialyzed into buffer C (50 mM TRIS–HCl pH
7.6) and loaded onto an ion exchange High Q column (Bio-
Rad, USA). The bound protein was eluted using a linear
NaCl gradient from 0 to 0.8M. The purifiedHisTag-PCNA
and StrepTag-PCNAwere dialyzed against buffer C supple-
mented with 150 mM NaCl, glycerol was added to a final
concentration of 15% (v/v), and proteins were frozen in liq-
uid nitrogen and stored at −80◦C for further experiments.
Tag-free human PCNA, and DNA pol  and ε, were pro-
duced and purified as described previously (25–27).
SELEX procedure and aptamer cloning
Selection of DNA aptamers was performed using the
SELEX method as described previously (28–30) with
minor modifications. Trimeric StrepTag-PCNA was used
as the selection target. The protein was covalently im-
mobilized to cyanogen bromide-activated Sepharose 4B
resin (Sigma-Aldrich, USA) according to the manufac-
turer’s instructions. The DNA library employed was
composed of molecules containing a 40-nucleotide ran-
dom region and two 20-nt specific flanking fragments
(5′-CATGCTTCCCCAGGGAGATG(N)40GAGGAA
CATGCGTCGCAAAC-3′). Sepharose beads with im-
mobilized human StrepTag-PCNA were mixed with 1 g
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of ssDNA (except for the first selection cycle in which
25 g of the synthetic DNA library was used) in buffer
D (137 mM NaCl, 12.3 mM KCl, 10 mM Na2HPO4, 2
mM KH2PO4, 5 mM MgCl2, 0.1% v/v Tween 20, pH
7.4) and incubated for 1 h at RT. Beads were then washed
seven times using buffer D and used as a template for
PCR in 50 l reactions containing 1 × PCR buffer (10
mM TRIS–HCl pH 8.8, 50 mM KCl, 0.08% v/v Nonidet
P40, 2.5 mM MgCl2), 500 M dNTPs, 1 M forward
(5′-CATGCTTCCCCAGGGAGATG-3′) and reverse
(5′-phosphate-GTTTGCGACGCATGTTCCTC-3′)
primers, 1.5 units of Taq polymerase (Thermo Scientific)
and the aptamer template. The reaction conditions were
94◦C for 5 min, followed by 24 cycles of 94◦C for 30 s,
55◦C for 30 s and 72◦C for 30 s, and a final amplification
at 72◦C for 5 min, performed in a gradient thermocycler.
The PCR product was precipitated using isopropanol, and
ssDNA for the next round of selection was prepared by
digestion of the PCR product with exonuclease Lambda
(Thermo Scientific, Lithuania) according to the protocol
supplied by the producer. Finally, ssDNA was purified
using a standard phenol/chloroform extraction procedure
followed by isopropanol precipitation. The quality and
concentration of ssDNA were evaluated by 8% DNA dena-
turing polyacrylamide gelelectrophoresis (PAGE). ssDNA
molecules obtained after 12 rounds of SELEX were cloned
into the pTZ57R/T vector using the InsTAclone PCR
Cloning Kit (Thermo Fisher Scientific), and constructs
were analyzed by DNA sequencing.
ELISA
Ni-coated microplates (Thermo Fisher Scientific) were
incubated with 15 pmol of HisTag-protein (PCNA or
GST, respectively) in 100 l of Phosphate-buffered saline
(PBS) o/n at 4◦C. Next, wells were washed three times
using PBS-T (PBS containing 0.05% v/v Tween-20) and
blocked using PBS supplemented with 1% (w/v) BSA
for 2 h at RT. After washing with PBS-T, biotinylated
A1 (5′-CATGCTTCCCCAGGGAGATGCCTATGG
TCCCCGCGTAGGTGGCAGCTCAAACCCGATTC
GAGGAACATGCGTCGCAAAC-3′) or reference (Ref;
5′-(ACTG) × 19 ACT -3′) aptamer was added to the
wells to a final concentration of 4 M and plates were
incubated for 1 h at RT with gentle agitation. After washing
with PBS-T to remove unbound aptamers, horseradish
peroxidase (HRP)-conjugated streptavidin (R&D Systems,
USA) was added to the wells and incubated for 30 min at
RT. Wells were washed again with PBS-T before the HRP
chromogenic substrate (R&D Systems) was added. The
reaction was stopped by addition of 1 M H2SO4, and the
absorbance at 450 nm was measured using a microplate
reader (Infinite-Pro Tecan 200, Tecan, Switzerland).
Pull-down assay
Pull-down assays were performed using a universal spin
column (MoBiTec, Germany) and High Capacity Strepta-
vidin Agarose (HCSA) Resin (Thermo Fisher Scientific).
HCSA resin suspension was washed with distilled water
and equilibrated with buffer AS (50 mM TRIS–HCl pH
7.5, 300 mM NaCl, 0.01% v/v Tween 20), and 20 l of
50% (w/v) streptavidin-agarose resin was incubated with
800 pmol of the 5′-biotinylated aptamer in 300 l of buffer
AS for 1 h at RT with gentle agitation. Beads were washed
three times with buffer AS (unless stated otherwise), incu-
bated with 2 nmol of HisTag-PCNA protein or 5 mg of to-
tal protein extract in 500 l of buffer AS for 1 h at 4◦C,
then washed four times with buffer AS. Aptamer-bound
protein was denatured by incubation in GLB buffer (50
mM TRIS–HCl pH 6.8, 2% w/v sodium dodecyl sulphate
(SDS), 2% w/v bromophenol blue, 10% v/v glycerol, 200
mM -mercaptoethanol) at 95◦C for 5 min. In the case of
PCNA purification from E. coli total protein extract, pro-
tein was first eluted with buffer AE (50 mM TRIS–HCl
pH 7.5, 500 mM NaCl, 300 mM guanidine hydrochloride,
0.01% v/v Tween 20), 2 × GLB buffer (50 mM TRIS–HCl
pH 6.8, 2% w/v SDS, 0.1% w/v bromophenol blue, 10%
v/v glycerol, 100 mM dithiothreitol (DTT)) was added and
the sample was denatured at 95◦C for 5 min. Samples were
analyzed by 12% (v/v) SDS-PAGE followed by Coomassie
brilliant blue staining.
-PCNA aptamer impact on PCNA/DNA pol  and
PCNA/DNA pol  interaction
DNA pol  containing the HisTag-p50 subunit (0.8 pmol)
was conjugated withNi SepharoseHigh Performance beads
(GE, Sweden), and 1.3 pmol of DNA pol ε was conjugated
with anti-FLAG M2 affinity gel (Sigma-Aldrich, USA) in
PDE buffer (25 mMHEPES-NaOH pH 7.8, 50 mMNaCl,
0.01% v/v NP40, 10% v/v glycerol). Beads were incubated
with 4 pmol of PCNA and 5 pmol of -PCNA or reference1
(Ref1; 5′-(ACTG) × 12 A-3′) aptamer in a 20 l volume
at 4◦C for 30 min. Subsequently, beads were washed three
times with PDE buffer (supplemented with 20 mM imida-
zole when DNA pol  was used), suspended in 2 x GLB
buffer and denatured at 95◦C for 3 min. Next, protein sam-
ples were separated by 10% (v/v) SDS-PAGE followed by
western blotting. DNA pol , DNA pol ε and PCNA were
detected using anti-p125 and -p261 antibodies, and anti-
human PCNA polyclonal serum, respectively.
Impact of -PCNA aptamer on DNA pol  and  binding to
30/90-mer primer-template DNA
A 100 pmol sample of 30/90-mer DNA template generated
by annealing 100 pmol of biotinylated 90-mer template
(5′-TGAGGTTCAGCAAGGTGATGCTTTAGATTTT
TCATTTGCTGCTGGCTCTCAGCGTGGCACTGT
TGCAGGCGGTGTTAATACTGACCGCCT-biotin-3′)
with 200 pmol of 30-mer primer (5′-CAGTGCCACGC
TGAGAGCCAGCAGCAAATG-3′) was conjugated with
50 l of Streptavidin Agarose Ultra Performance beads
(Solulink, USA). A 1 pmol sample of 30/90-mer DNA
template immobilized to streptavidin-agarose beads was
incubated with 1 pmol of PCNA, 300 fmol of DNA pol
 and 500 fmol of the indicated aptamer, or 1 pmol of
PCNA, 400 fmol of DNA pol ε and 250 fmol of the
indicated aptamer, at 4◦C for 10 min. Subsequently, beads
were washed three times with PDE buffer, suspended in
2 x GLB buffer and denatured at 95◦C for 3 min. Bound
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proteins were separated by 10% (v/v) SDS-PAGE followed
by western blotting. DNA pol  and ε were detected using
anti-p125 and -p261 antibodies, respectively.
Western blotting
Proteins were separated by 12% (v/v) SDS-PAGE and
transferred onto a PVDF membrane (Millipore, USA).
Membrane was washed three times with PBS-T, blocked
with 5% (w/v) milk in PBS-T (PBS-TM) and incubated
with primary antibody (1:10 000 dilution) or undiluted
serum o/n at 4◦C. After washing three times with PBS-
TM, the membrane was incubated with the appropriate
secondary antibody (1:10 000 dilution) for 1 h at RT. Af-
ter several washes, protein detection was performed using
Clarity Western ECL Blotting Substrate (Bio-Rad) and the
BioSpectrum Imaging System (UVP Ultra-Violet Products
Ltd, UK).
Computational analysis
Modeling of -PCNA aptamer secondary structure and
theoretical prediction of theGparameter were performed
using theMfold server (31). Calculations were performed at
25◦C with 300 mM NaCl.
K D determination by pull-down assay
A volume of 40 l of HCSA resin suspension (in excess to
bind all biotinylated aptamermolecules in each sample) was
washed with distilled water and equilibrated with buffer D
(137 mM NaCl, 12.3 mM KCl, 10 mM Na2HPO4, 2 mM
KH2PO4, 5 mMMgCl2, 0.1% v/v Tween 20, pH 7.4). Beads
were incubated in 60 l of buffer D with 5′-biotinylated -
PCNAaptamer (concentration range from 0 to 100M) for
1 h at RT with gentle agitation. Subsequently, the complete
immobilization of -PCNA aptamer to HCSA resin was
confirmed by measuring the absorbance at 260 nm. Next,
beads were washed five times with buffer D and incubated
with 100 nM HisTag-PCNA for 1 h at RT. After incuba-
tion, beads were centrifuged, 2 × GLB buffer was added
to the supernatant, and samples were incubated at 95◦C
for 5 min and separated by 12% (v/v) SDS-PAGE followed
by Coomassie brilliant blue staining. Densitometric anal-
ysis of the gel was performed using a Multispectral Imag-
ing System IMAGER with Launch VisionWorksLS (ver-
sion 6.8) software. The dissociation constant (KD) calcu-
lation was performed using GraphPad Prism software (La
Jolla, CA, USA). Using the equilibrium concentration of
HisTag-PCNA/-PCNA aptamer as a function of free -
PCNA aptamer (total aptamer), the KD of the tested com-
plex was calculated.
Calorimetric analysis of KD and binding stoichiometry
All isothermal titration calorimetry (ITC) experiments were
carried out at 25◦C using a VP-ITC instrument (MicroCal,
USA).HisTag-PCNAand-PCNAaptamer solutionswere
dialyzed overnight against buffer D. All solutions were de-
gassed under vacuum prior to use in ITC experiments. Typ-
ically, 25 injections of 650−703M -PCNA aptamer solu-
tion (ligand) were applied to the calorimeter cell (1.4355 ml
volume) filled with buffer D and 30−32 MHisTag-PCNA
(calculated as amonomer concentration). The first injection
was 3 l, and subsequent injections were 3, 8 or 10 l. The
injection speed was 0.5 l/s with 4 min intervals between
injections. To ensure proper mixing after each injection, a
constant stirring speed of 300 rpmwasmaintained through-
out the experiment. The -PCNA aptamer dilution (refer-
ence) experiments were analyzed according to the dimer dis-
sociation model provided in Origin software (version 7.0,
OriginLab, Northampton, MA, USA). In the case of com-
plex formation experiments, a double correction was used
prior to data analysis. First, the heat of the -PCNA ap-
tamer dilution was subtracted, and the mean value of the
heat after saturation was then subtracted. Data were ana-
lyzed according to the one set of sites model provided in
Origin 7.0 software.
Circular dichroism (CD) spectroscopy analysis
All circular dichroism (CD) spectroscopy measurements
were recorded on a JASCO J-710 (JASCO Co., Japan)
spectropolarimeter equipped with a circulating water bath
(JULABO Labortechnik GmbH, Germany). Buffer D was
used for all experiments. Spectra were recorded in the
range of 190−320 nm for the -PCNA aptamer, 190−250
nm for HisTag-PCNA and 240−320 nm for the -PCNA
aptamer/HisTag-PCNA complex, with 1 nm resolution.
The appropriate path length and sample concentrationwere
chosen for every measurement to maintain the photomulti-
plier voltage below 700 V. Three scanning acquisitions were
accumulated and averaged to yield the final spectrum. CD
spectra were corrected for the buffer baseline. The ellipticity
was recalculated to give the difference in extinction coeffi-
cients (ε) when possible. Spectra were normalized to path
length, peptide bond concentration for proteins and nu-
cleotide concentration for ssDNA. Temperature-dependent
measurements were performed using a 1 mm path length,
and a 17 or 34 M -PCNA aptamer concentration. The
signal at 270 nm was recorded over the range of 20−80◦C.
The heating or cooling rate was 1.0◦Cpermin. Raw temper-
ature scans were processed using Origin software (version
9.1.0) according to a simple model of two-state denatura-
tion assuming both H◦ and S are constant (i.e. CP =
0 for the melting transition).
DNA pol assay with oligo dT/poly dA primer-template DNA
DNA synthesis was performed in 5 l reactions contain-
ing buffer E (30 mMHEPES-NaOH pH 7.8, 7 mMMgCl2,
0.01% w/v BSA, 500 M DTT) supplemented with 50
M TTP, [-32P] TTP (Perkin Elmer, USA), 800 fmol of
oligo(dT)/poly(dA) (dT/dA) primer-template DNA (200
pmol as polynucleotide), 50 fmol of DNA pol  or ε, 1 pmol
of PCNA and the indicated amount of tested aptamer at
37◦C for 15 min. Each reaction mixture was adsorbed to
DE81 paper (Whatman, UK) and washed four times for
3 min each time with 0.5 M Na2HPO4. 32P-TMP incor-
porated into dT/dA was measured by Cherenkov counting
with a liquid scintillation counter (Beckman, USA).
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DNA pol assay with 28/90-mer primer-template DNA
A 10 pmol sample of 28-mer primer (5′-AGGCGGT
CAGTATTAACACCGCCTGCAA-3′) was labeled
with [ -32P] ATP (Perkin Elmer) using T4 polynu-
cleotide kinase (Clontech, USA) at 37◦C for 1 h
and purified by phenol-chloroform extraction and
ethanol precipitation. The labeled 28-mer primer was
mixed with a 1.5-fold molar excess of 90-mer template
(5′-TGAGGTTCAGCAAGGTGATGCTTTAGATTTT
TCATTTGCTGCTGGCTCTCAGCGTGGCACTGTT
GCAGGCGGTGTTAATACTGACCGCCT-3′). The
primer extension reaction was performed in a 5 l reaction
containing buffer E supplemented with 50 M dNTP,
800 fmol of labeled 28/90-mer primer-template DNA,
50 fmol of DNA pol  or ε, 1 pmol of PCNA and the
indicated amount of tested aptamer at 37◦C for 15 min.
Next, formamide dye (98% v/v deionized formamide,
10 mM EDTA, 0.025% w/v xylene cyanol, 0.025% w/v
bromophenol blue) was added and samples were incubated
at 95◦C for 3 min. Denatured samples were separated on a
10% (v/v) polyacrylamide gel containing 7 M urea in TBE
buffer (100 mM TRIS–HCl pH 8.0, 100 mM boric acid, 2
mM EDTA). The gel was fixed with a mixture of 15% (v/v)
methanol and 15% (v/v) acetic acid for 5 min, followed by
washing with water for 5 min. Products resulting from the
28-mer extension were detected by autoradiography with a
FLA-7000 phosphorimager (GE Healthcare, USA).
DNA pol assay with Ref1 or -PCNA aptamer as primer-
template DNA
A 10 pmol sample of aptamer was labeled with [ -32P]
ATP (Perkin Elmer) using T4 polynucleotide kinase at 37◦C
for 1 h and purified by phenol-chloroform extraction fol-
lowed by ethanol precipitation. Primer extension was per-
formed in a 5 l reaction mixture containing buffer E sup-
plemented with 50 M dNTP, 160 fmol of labeled Ref1 or
-PCNA aptamer, 80 fmol of DNA pol  or ε and 1 pmol
of PCNA at 37◦C for 15 min. Samples were then treated
as described above in the DNA pol assay with a 28/90-mer
primer-template DNA.
Electrophoretic mobility shift assay (EMSA)
A 10 pmol sample of the tested aptamer was labeled with
[ -32P] ATP using T4 polynucleotide kinase, and 10 fmol of
the tested aptamer was incubated in a 5 l reaction mixture
containing buffer E supplemented with 20 mMNaCl, 50 or
100 fmol ofDNApol or ε, 1 pmol of PCNA, and 0, 0.5 or 1
pmol of 28/90-mer primer-template DNA at 32◦C or on ice
for 10min. Aptamer/protein complexes were fixed for 5min
by addition of 0.5 l of 10% (v/v) glutaraldehyde at 32◦C.
The crosslinking reaction was terminated by addition of 0.5
l of electrophoretic mobility shift assay (EMSA) loading
buffer (100 mM TRIS-HCl pH 8.0, 20% w/v sucrose, 0.1%
w/v bromophenol blue). Next, samples were separated on a
5% (v/v) polyacrylamide gel in TAE buffer (40 mM TRIS–
HCl pH 8.0, 20 mM acetate, 1 mM EDTA). The gel was
fixed in a mixture containing 15% (v/v) methanol and 15%
(v/v) acetic acid for 5 min, followed by washing with water
for 5 min. The labeled aptamer was detected by autoradiog-
raphy with a FLA-7000 phosphorimager (GE Healthcare).
Statistical analysis
The significance of the effects of the presence of PCNA
(two levels: PCNA present or absent) and the type of ap-
tamer (three levels: Ref1 aptamer, -PCNA aptamer or no
aptamer) on DNA pol activity was assessed using two-
way ANOVA. When a significant effect of the type of ap-
tamer was detected with ANOVA, Tukey’s test was used
to assess differences in the means between particular types
of aptamers. Measured values were log-transformed before
analysis. Calculations were performed using R software. To
estimate the relative inhibitory concentration of aptamers
(half-maximal inhibitory concentration; IC50) onDNApol
activity, the 4-parameter logistic model was fitted to the re-
sults of DNA pol assays using Mathematica 9.0 (Wolfram
Research, USA).
RESULTS
Selection of anti-PCNA aptamers
The SELEX method was employed to generate a DNA
aptamer able to bind tightly to human PCNA. After 12
rounds of selection against StrepTag-PCNA, selected
aptamers were cloned and sequenced, and aptamer A1
(5′-CATGCTTCCCCAGGGAGATGCCTATGGTCCC
CGCGTAGGTGGCAGCTCAAACCCGATTCGAGG
AACATGCGTCGCAAAC-3′) was identified. The pull-
down assay was employed to verify the binding of A1 to
human PCNA, and unlike the Ref aptamer, A1 was able to
pull-down HisTag-PCNA from solution (Supplementary
Figure S1A). The binding of aptamer A1 to PCNA was
also subsequently confirmed using ELISA (Supplementary
Figure S1B).
Determination of the region of aptamer A1 required for
PCNA binding
To determine the region of aptamer A1 essential for effi-
cient binding to human PCNA, full-length A1 and variants
shortened at the 5′ or 3′ end (Table 1) were tested in pull-
down assays (Figure 1A). The −10/5′ variant bound only
∼25% of the amount of PCNA bound by the full-length
A1 aptamer (Figure 1B). Binding was not detected between
PCNA and the −20/5′ variant. Interestingly, the A1 ap-
tamer variant with 30 nt removed from the 3′ end (−30/3′)
bound ∼160% PCNA and was therefore ∼60% more effi-
cient than the full-length A1 aptamer. However, further re-
moval of nucleotides from the 3′ end (−40/3′ A1 aptamer
variant) led to a complete loss of affinity for PCNA. Thus,
the 49-nt A1 aptamer variant shortened only by 30 nt from
the 3′ end (5′-CATGCTTCCCCAGGGAGATGCCTAT
GGTCCCCGCGTAGGTGGCAGCTCA-3′ ssDNA) was
used for subsequent experiments and is referred to hence-
forth as the -PCNA aptamer. To verify the binding be-
tween the -PCNA aptamer and tag-free PCNA, the pro-
tein was overexpressed in E. coli. HCSA resin with immo-
bilized 5′-biotinylated aptamer was incubated with E. coli
total protein extract containing PCNA, unbound proteins
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Figure 1. Identification of the A1 aptamer region necessary for PCNA binding. (A) Pull-down analysis of the binding of A1 aptamer variants shortened at
the 5′ or 3′ end to PCNA. Aptamers were bound to streptavidin-agarose resin and incubated with HisTag-PCNA. After washing unbound proteins, bound
HisTag-PCNA was denatured, separated by 12% SDS-PAGE and stained with Coomassie brilliant blue. Lane M, protein mass marker; 1, full-length A1;
2, −10/5′ variant; 3, −20/5′ variant; 4, −10/3′ variant; 5, −20/3′ variant; 6, −30/3′ variant (referred to as the -PCNA aptamer); 7, −40/3′ variant. The
presented results are representative. (B) Densitometric analysis of HisTag-PCNA bound to A1 aptamer variants presented on panel (A). The results are
normalized relative to the signal from the protein sample bound to the full-length aptamer (100%). Results are means of triplicate measurements, and
errors represent standard deviation.
Figure 2. Representative putative secondary structure of the -PCNA ap-
tamer predicted by the Mfold server. The aptamer structure was modeled
using the Mfold web server at 25◦C and 300 mM NaCl.
were removed by washing and bound protein was eluted.
Unlike theRef1 aptamer (data not shown), the-PCNAap-
tamer bound to and successfully purified PCNA from the
mixture of bacterial proteins (Supplementary Figure S2A
and B).
Modeling the -PCNA aptamer secondary structure
To predict the putative secondary structure of the -PCNA
aptamer, computational analysis was employed using the
Mfold server. At 300 mMNa+ concentration and 25◦C, the
aptamer was predicted to potentially adopt two similar sec-
ondary structures, and the structure shown in Figure 2 with
a calculated free energy (G) of −6.62 kcal/mol is repre-
sentative.
Figure 3. Determination of the -PCNA aptamer/PCNA complex disso-
ciation constant by pull-down assay. Biotinylated -PCNA aptamer (con-
centration range from 0 to 100 M) bound to streptavidin-agarose resin
was incubated with 100 nM HisTag-PCNA. Unbound protein was de-
natured, separated by 12% SDS-PAGE and stained with Coomassie bril-
liant blue. Densitometric analysis of data from pull-down assays was per-
formed using a Multispectral Imaging System IMAGER with Launch Vi-
sionWorksLS. The dissociation constant (KD = 5.1 ± 0.59 M) of the
complex was calculated based on the equilibrium concentration ofHisTag-
PCNA/-PCNAaptamer as a function of free-PCNAaptamer (total ap-
tamer) using GraphPad Prism software. Results are the mean of triplicate
measurements, and error bars represent standard deviation.
Characterization of the -PCNA aptamer/PCNA complex
Determination of theKD. To evaluate the affinity of the -
PCNA aptamer for PCNA, two different approaches were
employed. The first was based on a pull-down assay in
which a constant amount of HisTag-PCNA was titrated
with increasing concentrations of-PCNAaptamer (Figure
3). Densitometric analysis of the resulting gel was used to
calculate the KD of the -PCNA aptamer/PCNA complex
from theHill slope of a one site-specific bindingmodel. ITC
was the second method used to characterize the -PCNA
aptamer/PCNA interaction. Similarly to the pull-down as-
say, HisTag-PCNA was titrated with increasing concentra-
tions of -PCNA aptamer. Exemplary raw isotherms of the
reference measurement and the -PCNA aptamer/PCNA-
binding reaction are presented in Figure 4A. Both processes
yielded similar endothermic deflections, but the heat of di-
lution of the -PCNA aptamer (reference) had a higher am-
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Table 1. A1 aptamer variants used in pull-down assays
A1 aptamer
variant name A1 aptamer variant sequence
Full length 5′-CATGCTTCCCCAGGGAGATGCCTATGGTCCCCGCGTAGGTGGCAGCTCAAACCCGATTCGAGGAACATGCGTCGCAAAC-3′
−10/5′ 5′-CAGGGAGATGCCTATGGTCCCCGCGTAGGTGGCAGCTCAAACCCGATTCGAGGAACATGCGTCGCAAAC-3′
−20/5′ 5′-CCTATGGTCCCCGCGTAGGTGGCAGCTCAAACCCGATTCGAGGAACATGCGTCGCAAAC-3′
−10/3′ 5′-CATGCTTCCCCAGGGAGATGCCTATGGTCCCCGCGTAGGTGGCAGCTCAAACCCGATTCGAGGAACATG-3′
−20/3′ 5′-CATGCTTCCCCAGGGAGATGCCTATGGTCCCCGCGTAGGTGGCAGCTCAAACCCGATTC-3′
−30/3′ 5′-CATGCTTCCCCAGGGAGATGCCTATGGTCCCCGCGTAGGTGGCAGCTCA-3′
−40/3′ 5′-CATGCTTCCCCAGGGAGATGCCTATGGTCCCCGCGTAGG-3′
Figure 4. Determination of the -PCNA aptamer/PCNA complex dissociation constant by ITC. (A) Raw calorimetric trace for -PCNA dissociation and
its titration into PCNA. (B) Integrated heats per mole of -PCNA injected into buffer (open squares, reference measurement) and -PCNA injected into
PCNA solution after subtraction of reference measurements (solid squares). Solid lines represent the best fit of the dimer dissociation model (open squares)
and the one set of sites model (solid squares) to experimental data. The calculated KD value is 2.00 ± 0.64 M.
plitude and decreased monotonically, unlike the titration of
-PCNA aptamer into HisTag-PCNA, which was accom-
panied by an initial increase followed by a distinct decrease.
The large heat deflections accompanying -PCNA aptamer
dilution indicate a change in oligomeric state at high con-
centration (Figure 4A). For reference data, application of
a simple dimer dissociation model provided a good fit, and
global analysis of data from three independent experiments
showed that the KD for reference measurements was 0.51 ±
0.08 mM, and the H◦ value was 52.7 ± 4.9 kJ/mol. The
failure to achieve a perfect fit between this model and the
obtained data may indicate a more complex mechanism of
dissociation, such as the presence of higher order oligomers
(data not shown). However, we assume that the monomeric
form of -PCNA dominates at low concentrations. The oc-
currence of dissociation during -PCNA aptamer dilution
suggests that reference measurements were not entirely cor-
rect, but the relatively high KD value implies that this ef-
fect could be ignored. Subtraction of reference data from
-PCNA aptamer/PCNA data resulted in an exothermic
sigmoidal signal, although the heat deflections did not de-
crease to zero by the end of the titration. The constant heat
deflection accompanying the final few injections indicates
a slight buffer mismatch resulting from incomplete dialysis
of the protein. Based on this interpretation, the mean value
of final five injections was treated as the offset value and
subtracted from all data prior to further analysis. The fi-
nal isotherm is shown in Figure 4B (solid squares). Binding
of the -PCNA aptamer to PCNA was correctly described
by the one set of sites model. The calculated mean val-
ues of thermodynamic parameters, summarized in Table 2,
Table 2. Thermodynamic parameters of the -PCNA aptamer/PCNA
complex based on ITC analysis
N 0.48 ± 0.11
KA (M−1) 499 000 ± 160 000
KD (M) 2.00 ± 0.64
H◦ (kJ/mol) −20.63 ± 1.38
S◦ (J/mol K) 39.54 ± 2.15
G◦ (kJ/mol) −32.5 ± 0.8
N= stoichiometry;KA andKD = association and dissociation constants, respectively;
H, S and G = enthalpy, entropy and Gibbs free energy changes, respectively.
showed that the formation of the -PCNA aptamer/PCNA
complex was driven by both enthalpy and entropy. The ob-
tained stoichiometry of 0.48 suggests that one PCNA trimer
binds to 1.44 -PCNA molecules.
CD spectroscopy analysis of the -PCNA aptamer
CD spectroscopy was employed to analyze the secondary
structure of the-PCNAaptamer. The position and low rel-
ative intensity of the positive long wavelength band at∼270
nm and the negative band at ∼245 nm suggests that the -
PCNA aptamer partially adopts a typical B-form confor-
mation (Figure 5A). Thermal denaturation of the -PCNA
aptamer was monitored to investigate its stability. The peak
at 270 nm represents the maximum change in the CD spec-
trum; hence it was chosen to monitor aptamer unfolding.
Sequential spectra were collected between 20 and 80◦C in
both increasing and decreasing directions, which confirmed
the fully reversible nature of -PCNA aptamer denatura-
tion (Figure 5B). The presence of isodichroic points at 231.5
and 256.5 nm (Figure 5A, inset) implies a simple two-state
mechanism for aptamer structural changes. Global analysis
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Figure 5. CD spectroscopic characterization of the -PCNA aptamer as a function of temperature. (A) CD spectrum of the -PCNA aptamer measured
at 20◦C. Inset shows CD spectra of the -PCNA aptamer measured at 20◦C (blue line), 45◦C (black dotted line), 60◦C (red line) and 80◦C (green line). (B)
Averaged thermal denaturation profile of the -PCNA aptamer measured at 270 nm, based on three increases and two decreases of temperature. The folded
fraction (ffold) of the -PCNA aptamer was calculated according to the estimated values of fully folded and unfolded forms. The line (red) is calculated
based on the self-complementary strand melting model with Tm = 51.4◦C and H◦ = −68.6 kJ/mol.
of all recorded traces was performed based on themelting of
self-complementary strand model with shared values of Tm
and H◦, and without thermal dependence of the elliptic-
ity for folded and unfolded forms of the -PCNA aptamer.
Thismodel provided a very good fit for the data and gave the
following parameters: Tm = 51.4 ± 0.2◦C, H◦ = −68.6 ±
1.0 kJ/mol, S◦ = −211 ± 3 J/mol K and G◦25◦C = −5.9
± 0.1 kJ/mol. The obtained parameters show that 91% of
-PCNA aptamer molecules were folded at 25◦C, and 77%
were folded at 37◦C.
To test whether the binding of the -PCNA aptamer to
the target protein changes the structure of the aptamer, CD
spectra analysis was limited to 250−320 nm, where the pro-
tein signal is typically significantly lower than the nucleic
acid signal. Additionally, a >11-fold excess of protein was
used to maximize DNA complexation. This CD analysis
revealed evident differences between the summed spectra
of independently measured -PCNA aptamer and HisTag-
PCNA, and spectra of the complex (Figure 6A). Spectral
decomposition was performed according to calorimetric
data, which revealed that the bound fractions of -PCNA
aptamer and HisTag-PCNA under these experimental con-
ditions were 0.96 and 0.18, respectively. Using data from a
sample composed of -PCNA aptamer andHisTag-PCNA,
the spectrumof the complexwas calculated according to the
following formula: (total spectrum recorded for complex
mixture) – (0.04× spectrum recorded for -PCNA aptamer
+ 0.82 × spectrum recorded for HisTag-PCNA). To obtain
a spectrum in which presumably no structural changes in
substrates took place during complex formation, a simple
sum of -PCNA aptamer and HisTag-PCNA spectra mea-
sured separately based on their participation in the com-
plex was calculated using the following formula: (0.96 × -
PCNAaptamer+ 0.18×HisTag-PCNA). The observed dif-
ference between both spectra was significant and associated
with a shift in the wavelengthmaximum from 278 to 270 nm
Figure 6. Near-UV CD spectroscopy analysis of -PCNA aptamer and
PCNA association. Association of -PCNA aptamer with PCNA was an-
alyzed by CD. (A) Spectra of the -PCNA aptamer (blue half-diamonds),
HisTag-PCNA (red triangles) and -PCNA aptamer/HisTag-PCNA (ra-
tio, 1:11; open circles), and the calculated sum of separately measured -
PCNA aptamer and HisTag-PCNA spectra (green squares). (B) Spectra
of the -PCNA aptamer/PCNA complex without (open circles) and with
(black solid circles) structural changes assumed.
(Figure 6B). This indicates changes in the secondary and/or
tertiary structure of the participants as a result of complex
formation. Hypsochromic shift rather cannot be attributed
to the transition of PCNA aromatic amino acids because
it would reflect changes of PCNA structure. Given stabil-
ity and ordered structure of PCNA, under the experimen-
tal conditions employed, changes in the -PCNA aptamer
structure likely caused the observed differences.
Effect of the -PCNA aptamer on DNA replication
To elucidate the impact of the -PCNA aptamer on DNA
replication, a set of in vitro assays was performed. First,
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Figure 7. Evaluation of the -PCNA aptamer as a potential primer-
template DNA for DNA pol  and ε. Extension of 160 fmol of 5′ 32P-
labeled Ref1 and the -PCNA aptamer by DNA pol  or ε was tested in
the presence or absence of PCNA. Only the -PCNA aptamer, in the ab-
sence of PCNA, was used as a primer-template DNA by both DNA pol 
and ε. Exonuclease degradation of 160 fmol of -PCNA or Ref1 aptamer
by DNA pol  or ε was observed in the absence of PCNA. In the presence
of PCNA and DNA pol  or ε, degradation of Ref1 but not -PCNA ap-
tamer was detected. Samples were separated by 10% polyacrylamide gel
containing 7 M urea. The signal was detected by autoradiography. Pre-
sented results are representative.
binding of the -PCNA aptamer to HisTag-PCNA was as-
sessed at 25 and 37◦C, and interaction between PCNA and
the -PCNA aptamer was observed at both temperatures
(Supplementary Figure S3). Based on the modeled puta-
tive secondary structure of the-PCNAaptamer (Figure 2),
we next tested whether it could serve as a primer-template
DNA for DNA pol  or ε. In the absence of PCNA, the -
PCNA aptamer was used by both DNA pol enzymes as a
primer-template DNA, albeit with very low efficiency, but
the reference (Ref1) aptamer was not used (Figure 7). By
contrast, in the presence of PCNA, neither DNA pol  nor
ε was able to use the -PCNA or Ref1 aptamer as a primer-
template DNA. In the same experiment, the ability of the
-PCNA aptamer to function as a substrate for the exonu-
cleolytic activity of DNA pol  or ε was verified. We found
that, in the absence of PCNA, both -PCNA and Ref1 ap-
tamers were degraded. However, when PCNA was present
in the reaction mixture, the -PCNA but not the Ref1 ap-
tamer was protected against the exonucleolytic activity of
DNA pol  and ε.
Subsequently, the impact of the -PCNA aptamer on
the activity of human DNA pol  (using a dT/dA primer-
template DNA) was tested in the presence or absence of
PCNA. This experiment clearly showed no significant im-
pact of either the -PCNA or Ref1 aptamer on DNA pol
 activity in the absence of PCNA (Figure 8A). However,
unlike the Ref1 aptamer, the -PCNA aptamer inhibited
the activity of DNA pol  in the presence of PCNA (Fig-
ure 8A). Moreover, in the presence of PCNA and the -
PCNA aptamer, the activity of DNA pol  was ∼3-fold
lower than in the absence of PCNA and the presence of
the -PCNA aptamer. To evaluate the efficiency of DNA
pol  inhibition, the IC50 of the -PCNA aptamer was de-
termined (Figure 8B) and found to be in the nM range. In
the next experiment, the impact of the -PCNA aptamer
on the activity of DNA pol  was tested using a 28/90-mer
primer-template DNA (Figure 8C). At a concentration of
300 nM -PCNA aptamer, the activity of DNA pol  was
undetectable. As in the previous experiment (using a dT/dA
primer-template DNA), the IC50 value of the -PCNA ap-
tamer was also in the nM range when the 28/90-mer primer-
template DNA was used (Figure 8D). Additionally, a de-
tailed analysis of 28-mer DNA extension (Figure 8C) in the
absence of PCNA revealed the production of intermediate
DNA replication products by DNA pol  (Figure 8C, lane
11; PCNA-independent activity of DNA pol ). Moreover,
in the absence of PCNA and the presence of the -PCNA
aptamer, PCNA-independent DNA pol  activity was not
inhibited (Figure 8C, lane 12). However, in the presence of
PCNA, the -PCNA aptamer inhibited both the PCNA-
dependent and PCNA-independent activity of DNA pol .
Next, the impact of the -PCNA aptamer on DNA pol
ε activity was analyzed. In the absence of PCNA, when a
dT/dA primer-template DNA was used, a similar level of
DNA pol ε inhibition was observed in the presence of both
the -PCNA and Ref1 aptamers (Figure 9A). Thus, this
inhibition was probably due to the presence of an excess
of oligonucleotides. However, in the presence of PCNA, a
statistically significant difference between the -PCNA and
Ref1 aptamer, in the context of DNA pol ε activity inhibi-
tion, was clearly visible. Moreover, the difference in DNA
pol ε activity in the presence of either only the -PCNA ap-
tamer, or both PCNA and the -PCNA aptamer, was also
statistically significant. Testing the impact of the -PCNA
aptamer on the activity of DNA pol ε using a 28/90-mer
primer-template DNA yielded similar results to those ob-
tained for the dT/dA primer-template DNA (Figure 9A, C
and D). In both cases, the IC50 value of the aptamer was in
the nM range.
Influence of the -PCNA aptamer and PCNA on -PCNA
aptamer/PCNA/DNA pol complex formation
Analysis of the data from our studies indicated that the
mechanism underlying the inhibition of DNA pol en-
zymes was not simply due to interference with the DNA
pol/PCNA interaction. Therefore, we next tested whether
the -PCNA aptamer, PCNA and DNA pol  or ε could
form ternary complexes. Appropriate mixtures composed
of DNA aptamer, PCNA and/or DNA pol were prepared,
incubated at 4◦C, fixed with glutaraldehyde and assessed
by EMSA. The results demonstrated that binding between
PCNA and DNA pol  or ε was not abolished in the pres-
ence of the -PCNA aptamer, and the aptamer was present
in the complex with PCNA (Supplementary Figure S4) as
well as the complex with DNA pol  or ε, although only
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Figure 8. The impact of the -PCNA aptamer on DNA pol  activity in the presence or absence of PCNA. (A) Incorporation of 32P-TMP into a dT/dA
primer-template DNA by DNA pol  in the presence or absence of PCNA and 100 nM -PCNA or reference1 (Ref1) aptamer. The relative amount
of 32P-TMP incorporation was normalized against the mean amount of 32P-TMP incorporated in the presence of PCNA and absence of aptamer. (B)
Incorporation of 32P-TMP into a dT/dA primer-template DNA by DNA pol  in the presence of PCNA and increasing concentrations of -PCNA
aptamer (0.14, 0.4, 1.2, 3.6, 11.0, 33.0, 100 and 300 nM). Values are normalized against the amount of 32P-TMP incorporated in the absence of the -
PCNA aptamer. (C) Extension of a 5′ 32P-labeled 28-mer primer complexed with a 90-mer DNA template by DNA pol  in the presence or absence of
PCNA and -PCNA or Ref1 aptamer. Lanes: 1, 0; 2, 0.14; 3, 0.4; 4, 1.2; 5, 3.6; 6, 11; 7, 33; 8, 100; 9, 300; 10, 300; 11, 0; 12, 300 nM aptamer. Samples were
separated on a 10% polyacrylamide gel containing 7M urea. The signal was detected by autoradiography. (D) Signals from fully elongated 28-mer products
presented on panel (C) quantified using ImageJ software. Values are normalized against the amount of full-length product in the absence of the -PCNA
aptamer. Results in (A), (B) and (D) are the means of three independent experiments. Results in (C) are representative. Error bars represent standard error.
Asterisks indicate statistically significant differences: *P = 0.01−0.05; **P = 0.001−0.01; ***P < 0.001 (Tukey’s test).
in the presence of PCNA (Figure 10A and B; lanes 11 and
12). Comparison of EMSA results obtained at 4◦C (Figure
10A and B; lanes 9−12) and 32◦C (Figure 11A and B; lanes
9−12) before glutaraldehyde treatment revealed an addi-
tional protective effect of PCNA against the exonuclease
activity of DNA pol  and ε with respect to the -PCNA
aptamer (similarly as observed in the previous experiment
(Figure 7)). Moreover, subsequent pull-down and immuno-
precipitation experiments revealed that binding of PCNA to
DNA pol enzymes was enhanced in the presence of the -
PCNA aptamer but not the Ref1 aptamer (Figure 12). Pull-
down experiments with 30/90-mer primer-template DNA
beads indicated that the -PCNA aptamer but not the Ref1
aptamer could suppress the binding of DNA pol  and
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Figure 9. The impact of the -PCNA aptamer on DNA pol ε activity in the presence or absence of PCNA. (A) Incorporation of 32P-TMP into a dT/dA
primer-template DNA by DNA pol ε in the presence or absence of PCNA and 100 nM -PCNA or reference1 (Ref1) aptamer. The relative amount of 32P-
TMP incorporationwas normalized against themean amount of 32P-TMP incorporated in the absence of PCNAand absence of aptamer. (B) Incorporation
of 32P-TMP into a dT/dA primer-template DNA by DNA pol ε in the presence of PCNA and increasing concentrations of -PCNA aptamer (0.14, 0.4,
1.2, 3.6, 11.0, 33.0, 100 and 300 nM). Values are normalized against the amount of 32P-TMP incorporated in the absence of the -PCNA aptamer. (C)
Extension of a 5′ 32P-labeled 28-mer primer complexed with a 90-mer DNA template by DNA pol ε in the presence of -PCNA or Ref1 aptamer. Lanes: 1,
0; 2, 0.14; 3, 0.4; 4, 1.2; 5, 3.6; 6, 11; 7, 33; 8, 100; 9, 300; 10, 300; 11, 0; 12, 300 nM aptamer. Samples were separated on a 10% polyacrylamide gel containing
7 M urea. The signal was detected by autoradiography. (D) Signals from fully elongated 28-mer products presented on panel (C) (lanes 11, 12, 1, 10 and
9) were quantified by ImageJ software. The relative amount of full-length product was normalized against the mean amount of the full-length product
in the presence of PCNA and absence of aptamer. (E) The signal from the fully elongated 28-mer products (lanes 2–9) presented on panel (C). Values
were normalized against the amount of full-length product in the absence of the -PCNA aptamer. Results in (A), (B), (D) and (E) are the mean of three
independent experiments. Error bars represent standard error. Asterisks indicate statistically significant differences: *P = 0.01−0.05; **P = 0.001−0.01;
***P < 0.001 (Tukey’s test). Results in (C) are representative.
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Figure 10. Analysis of -PCNA aptamer, PCNA and DNA pol complex formation at 4◦C by electrophoretic mobility shift assay (EMSA). A 10 fmol
sample of 5′ 32P-labeled Ref1 or -PCNA aptamer, and 50 (+) or 100 (++) fmol of DNA pol  (A) or DNA pol ε (B), were incubated with or without 1
pmol of PCNA on ice for 10 min. Next, the mixture was fixed with glutaraldehyde at 32◦C, products were separated on a 5% polyacrylamide gel and the
signal was detected by autoradiography. Results in (A) and (B) are representative.
Figure 11. Analysis of -PCNA aptamer, PCNA and DNA pol complex formation at 32◦C by electrophoretic mobility shift assay (EMSA). A 10 fmol
sample of 5′ 32P-labeled Ref1 or -PCNA aptamer, and 50 (+) or 100 (++) fmol of DNA pol  (A) or DNA pol ε (B), were incubated with or without 1
pmol of PCNA at 32◦C for 10 min before glutaraldehyde fixation. Products were separated on a 5% polyacrylamide gel, and the signal was detected by
autoradiography. Results in (A) and (B) are representative.
ε to the 30/90-mer primer-template DNA in the presence
of PCNA (Figure 13). Further comparison of the stability
of -PCNA aptamer/PCNA/DNA pol  (Figure 14, lanes
8−10) and -PCNA aptamer/PCNA/DNA pol ε (Figure
14, lanes 14−16) complexes, in the presence of excess 28/90-
mer primer-template DNA, demonstrated that only the lat-
ter could be outcompeted by excess primer-template DNA.
This suggests that the complex containing DNA pol  is
more stable than the complex with DNA pol ε.
DISCUSSION
PCNA is one of several proteins that work together at
the heart of the DNA replication machinery. PCNA is
considered a non-oncogenic target for anti-cancer therapy
(15–17), and molecules that inhibit or otherwise control
PCNA function might prove useful in the development
of novel cancer treatments. Previous in vitro data showed
that short peptides can control PCNA function, such as
PIP-box (32) and APIM motif-based peptides (13,33) that
block interactions between PCNA and proteins contain-
ing these motifs. Moreover the Y211F peptide blocks phos-
phorylation of PCNA tyrosine 211 (19). Other experiments
demonstrated that the T3 hormone triiodothyronine and
its analog T2AA (the amino alcohol of T3 lacking hor-
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Figure 12. The impact of the -PCNA aptamer on the PCNA/DNA pol
interaction. An 800 fmol sample of DNA pol  (A) and 1300 fmol of DNA
pol ε (B) were bound to Ni-NTA and agarose-protein anti-FLAG M2
affinity beads, respectively. Beads were incubated with 4 pmol of PCNA
in the presence and absence of 5 pmol of reference1 (Ref1) or -PCNA ap-
tamer. After incubation, unbound protein was removed by washing, and
proteins bound to beads were denatured, separated by 10% SDS-PAGE
and subjected to western blotting. DNA pol  and ε and PCNA were de-
tected using anti-p125 and -p261 antibodies, and anti-human PCNA poly-
clonal serum, respectively. The presented results are representative.
mone activity) can block the PCNA/PIP-box interaction
(34). Moreover, T2AA and its analogs can suppress transle-
sion DNA synthesis (34), which allows the DNA repli-
cation machinery to replicate past DNA lesions such as
pirymidine dimers or apurinic/apyrimidinic sites (35,36).
Another small molecule, PCNA-I1, inhibits the association
of PCNA with chromatin (37).
In the early stages of the present work, after identifying
the A1 aptamer, we found that the affinity of the A1 ap-
tamer variant truncated at the 5′ end towards PCNA was
significantly reduced (Figure 1). This indicated that the 5′
region might be involved in PCNA binding and/or be cru-
cial for adoption of the correct aptamer structure. By con-
trast, the 3′ end of the A1 aptamer was superfluous, and
deletion did not affect aptamer activity.Moreover, the affin-
ity of the -PCNA aptamer (A1 aptamer variant truncated
at the 3′ end) toward PCNAwas higher than that of the full-
length A1 aptamer. This indicates that the 30 nt at the 3′ end
of theA1 aptamermay sterically hinder and thereby prevent
an optimal fit between the aptamer and PCNA. The sec-
ondary structure of the modeled -PCNA aptamer, which
mimics the DNA replication fork (Figure 2), indicates that
the central cavity of the PCNA ring is probably located on
the dsDNA fragment close to the dsDNA/ssDNA inter-
face. This is unsurprising because, during DNA replication,
PCNA is loaded near the primer-template DNA junction
to coordinate replicative DNA pol enzymes (38). Moreover,
an -PCNA aptamer blocked at the 5′ terminus by strepta-
vidin (Figure 1), which is unable to enter the cavity of the
PCNA ring, could still interact with PCNA. This indicates
that postulated localization of PCNA on the dsDNA frag-
ment of the-PCNAaptamer is not essential for interaction
between the -PCNA aptamer and PCNA, and the exact
nature of the specific interaction must involve other parts.
Unfortunately, our attempts to solve the crystal structure
of the -PCNA aptamer/PCNA complex were unsuccess-
ful; hence we employed CD analysis, which revealed less
correctly folded -PCNA aptamer at 37◦C than at 25◦C.
Perhaps this effect could be eliminated if the aptamer se-
lection process was performed at 37◦C. Moreover, the CD
spectrum of the -PCNA aptamer was typical of B-form
DNA, and CD analysis indicated that, during complex for-
mation, the structure of the -PCNA aptamer became al-
tered, but the structure of PCNA did not change. This is
understandable given the stable and highly ordered struc-
ture of the PCNA trimer under the experimental condi-
tions employed. To further investigate the properties of the
-PCNA aptamer/PCNA complex, we determined the KD
value using pull-down assays and ITC, and KD values ob-
tained by both techniques were in the M range. However,
the KD value from pull-down assays was over 2-fold higher
than the value from ITC (5.1 M versus 2.0 M; Figures 3
and 4,), which is insignificant in the context of understand-
ing the impact of the -PCNA aptamer on DNA replica-
tion. This apparent discrepancy possibly results from differ-
ences in the accuracy of the twomethods. Although we can-
not exclude the trace leakage of biotinylated aptamer from
streptavidin during the experiment, the strong binding be-
tween streptavidin and biotin (KD ∼10−14 M) (39) makes
this unlikely to have a significant impact on the measured
KD value. Interestingly, the stoichiometry of the -PCNA
aptamer/PCNA (trimer) complex calculated from ITC data
was 1.44. The fractional value could be due to inaccurate ss-
DNA and protein concentration determinations.
To test the impact of the -PCNAaptamer on the activity
of DNA pol  and ε, we first checked whether the DNA pol
enzymes could extend the 3′ end of the -PCNA aptamer,
but the -PCNA aptamer was unable to sufficiently mimic
the primer-template DNA structure (Figure 7). Moreover,
protection of the -PCNA aptamer by PCNA against the
exonucleolytic activity of DNA pol  and ε was not surpris-
ing, since the -PCNA aptamer secondary/tertiary struc-
ture formed upon PCNA binding was presumably largely
inaccessible to the DNA pol regions exhibiting exonucle-
ase activity. When we tested the impact of the -PCNA ap-
tamer and PCNA on DNA synthesis by DNA pol  and
ε, several unexpected features were observed. First, the -
PCNA aptamer inhibited both DNA pol enzymes at nM
concentrations in the presence of PCNA (Figures 8 and 9).
Themeasured IC50 values of the-PCNAaptamer for both
DNA pol enzymes (nM) were three orders of magnitude
lower than theKD (M) between the -PCNA aptamer and
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Figure 13. The impact of the -PCNA aptamer and PCNA on the 30/90-mer primer-template DNA/DNA pol  or ε complex. A 300 fmol sample of
DNA pol  (A) and 400 fmol of DNA pol ε (B) were incubated with 1 pmol of 30/90-mer primer-template DNA immobilized on streptavidin-agarose
beads in buffer with or without 1 pmol of PCNA, and with 500 fmol (A) or 250 fmol (B) of reference1 (Ref1) or -PCNA aptamer. After incubation, beads
were washed, and bound protein was denatured, separated by 10% SDS-PAGE and subjected to western blotting. DNA pol  and ε were detected using
anti-p125 and -p261 antibodies, respectively. The presented results are representative.
Figure 14. Stability of the -PCNA aptamer/PCNA/DNA pol  and -PCNA aptamer/PCNA/DNA pol ε complexes in the presence of 28/90-mer
primer-template DNA. A 10 fmol sample of 5′ 32P-labeled -PCNA aptamer, and 50 fmol of DNA pol  or DNA pol ε, were incubated with or without 1
pmol of PCNA and 0, 0.5 or 1 pmol of 28/90-mer primer-template DNA at 4◦C for 10 min before glutaraldehyde fixation. Products were separated on a
5% polyacrylamide gel, and the signal was detected by autoradiography. The presented results are representative.
PCNA measured by pull-down assays and ITC. In the ab-
sence of PCNA, the -PCNA aptamer did not affect DNA
synthesis by DNA pol  (Figure 8A and C), suggesting that
the aptamer did not block/bind DNA pol  directly. In the
case of DNA pol ε, DNA synthesis in the absence of PCNA
was slightly inhibited by 300 nM-PCNAorRef1 aptamers
(Figure 9A). We concluded that this was non-specific in-
hibition of DNA pol ε by addition of excess non-primer-
template DNA. Similar effect was previously described for
yeast DNA pol ε, which was shown to bind ssDNA as well
as dsDNA in the absence of PCNA, and ssDNAblocked the
activity of yeast DNA pol ε in a non-specific manner (40).
Moreover, DNA pol activity assays revealed that addition
of both the -PCNAaptamer and PCNA toDNApol or ε
reduced DNA synthesis levels to below those in the absence
of PCNA (Figures 8A and 9A white bars - comparison be-
tween PCNA (−) and (+)). If the -PCNA aptamer sim-
ply blocked the formation of PCNA/DNA pol complexes,
DNA synthesis with saturating -PCNA aptamer would be
comparable to that without PCNA, but not lower. Given
that (i) a stable complex between calf thymus DNA pol 
and dsDNA containing a protruding 5′ end forms in the
presence of PCNA (41), (ii) the -PCNA aptamer in the
modeled non-functional primer-template DNA junction-
like structure has a protruding 5′ end (Figure 2) and (iii)
DNA pol activity assays yielded a nM IC50 of the -PCNA
aptamer (Figures 8 and 9), we concluded that the -PCNA
aptamer, PCNA and DNA pol enzymes potentially form
novel -PCNA aptamer/PCNA/DNA pol complexes that
are hardly accessible to the primer-template DNA.
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Figure 15. Putative model of -PCNA aptamer/PCNA complex-dependent inhibition of DNA replication. The -PCNA aptamer and primer-template
DNA appear to compete for binding to the PCNA/DNA pol /ε complex. The -PCNA aptamer-specific inhibition of DNA pol is dependent on the
presence of PCNA. (1) In the absence of the -PCNA aptamer, the primer-template DNA forms a tri-molecular complex with PCNA and DNA pol  or
ε, and replication of the DNA template is undisturbed; (2) In the presence of the -PCNA aptamer, rather than primer-template DNA/PCNA/DNA pol
 or ε complex formation, assembly of the -PCNA aptamer/PCNA/DNA pol  or ε complex is favored. The -PCNA aptamer/PCNA/DNA pol  or ε
complex blocks formation of a primer-template DNA/PCNA/DNA pol /ε complex, thereby preventing template DNA replication.
Based on the results of DNA pol /ε activity assays and
ITC experiments, we built a preliminary model of the -
PCNA aptamer/PCNA complex-dependent mechanism of
DNApol /ε activity inhibition. Given that (i) the -PCNA
aptamer inhibited the activity of DNA pol  only in the
presence of PCNA (Figure 8), (ii) the -PCNA aptamer
effectively inhibited the activity of DNA pol /ε at low
nM concentrations (e.g. 10 nM) in the presence of excess
PCNA (200 nM) and DNA template (160 nM; Figures 8
and 9), despite the fact that the -PCNA aptamer/PCNA
complex KD value was in the M range (Figure 5), (iii)
the strength of the -PCNA aptamer-dependent inhibi-
tion of DNA pol /ε activity was enhanced in the pres-
ence of PCNA (Figures 8 and 9) and (iv) excess PCNA
(200 nM) did not affect the activity of DNA pol  in the
presence of stoichiometric concentrations of -PCNA ap-
tamer (10 nM) and DNA pol  (10 nM), we concluded that
the determined nM IC50 value reflects a KD in the nM
range or lower for the association of the bi-molecular -
PCNA aptamer/PCNA complex with DNA pol enzymes.
Presumably, the -PCNA aptamer/PCNA/DNA pol com-
plex KD must be much lower than that of the -PCNA
aptamer/PCNA (Figures 10 and 11) and PCNA/DNA
pol /ε complexes. Unfortunately, we could not directly
measure this value using ITC due to technical limita-
tions (insufficient production of DNA pol enzymes). This
raises the important question: which factors are respon-
sible for the increased stability of the tri-molecular com-
plex (-PCNA aptamer/PCNA/DNA pol) compared with
the bi-molecular complexes (-PCNA aptamer/PCNA and
PCNA/DNA pol)? We cannot exclude the possibility that
a change in the -PCNA aptamer structure may stabi-
lize the -PCNA aptamer/PCNA/DNA pol tri-molecular
complex. Another possibility is that aptamer structural
changes are not significant and the higher stability of the
tri-molecular complex is a result of additional favorable in-
teractions between the components of the complex, i.e. -
PCNA aptamer/DNA pol, -PCNA aptamer/PCNA and
PCNA/DNA pol (e.g. via the PIP-box motif). In this case,
the -PCNA aptamer could mimic a non-functional DNA
replication fork structure.
To verify our hypothesis that a tri-molecular com-
plex is formed, additional experiments were con-
ducted to investigate (i) the formation of the -PCNA
aptamer/PCNA/DNA pol complex (Figures 10 and 11),
(ii) the impact of the -PCNA aptamer on PCNA/DNA
pol complex stability (Figure 12), (iii) the impact of the
-PCNA aptamer and/or PCNA on primer-template
DNA/DNA pol complex stability (Figure 13) and
(iv) the impact of primer-template DNA on -PCNA
aptamer/PCNA/DNA pol complex stability (Figure 14).
The results presented in Figures 10 and 11 revealed a poor
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signal from the -PCNA aptamer/PCNA bi-molecular
complex, consistent with the KD value determined by ITC
(Figure 4) and supporting our calculation. Moreover, these
results confirmed our hypothesis that the -PCNA aptamer
formed a complex with PCNA/DNA pol, but it did not
block the formation of complexes composed of PCNA and
DNA pol enzymes involved in DNA replication (previously
shown to act in complex with PCNA during DNA replica-
tion) (7). Rather, the -PCNA aptamer strengthened the
affinity between PCNA and DNA pol enzymes (Figure 12).
Subsequent data from DNA pol activity assays (Figures 8
and 9) and EMSA (Figure 14) indicated the higher stability
of the -PCNA aptamer/PCNA/DNA pol  complex
relative to the -PCNA aptamer/PCNA/DNA pol ε
complex. This conclusion was based on the fact that a 50-
to 100-fold higher amount of 28/90-mer primer-template
DNA was unable to displace the -PCNA aptamer from
the -PCNA aptamer/PCNA/DNA pol  complex (Figure
14). This is particularly interesting in the context of DNA
replication, and suggests that the -PCNA aptamer might
block DNA replication, resulting in uncoordinated leading
and lagging DNA strand replication. In principle, an
appropriate amount of -PCNA aptamer could completely
block replication of the leading DNA strand, mediated by
DNApol ε but not lagging DNA strand, mediated byDNA
pol . In the future, it would be interesting to develop an
aptamer with a significantly lower affinity for PCNA/DNA
pol  but an undisturbed affinity for PCNA/DNA pol ε,
or vice versa. Moreover, in the context of DNA replication,
it would be especially interesting to analyze the impact of
the -PCNA aptamer on other DNA pol enzymes that
cooperate with PCNA, such as those belonging to the
Y-family (e.g. DNA pol , , 	 or Rev1), to assess whether,
and if so how, the -PCNA aptamer affects their activity.
CONCLUSION
Given the potential of PCNA as a non-oncogenic anti-
cancer therapeutic target (16), in this study we developed
and characterized the -PCNA aptamer. Based on the re-
sults, we propose that the -PCNA aptamer, which un-
dergoes a change in secondary structure upon binding to
PCNA, blocks replication of the DNA template by form-
ing an -PCNA aptamer/PCNA/DNA pol complex that is
unable to bind the primer-template DNA (Figure 15). The
proposed model of the -PCNA aptamer-dependent inhi-
bition of DNA replication differs substantially from those
previously reported for molecules controlling PCNA func-
tions (13,18,19,32). Finally, although our experiments did
not indicate that the -PCNA aptamer inhibits the forma-
tion of complexes between PCNA and humanDNA pol en-
zymes, we cannot exclude this possibility for other proteins
that use PCNA as a sliding platform (42,43).
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